Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection

BACKGROUND/AIMS: The Social Security System of our country reimburses only paritaprevir, ritonavir, ombitasvir, and dasabuvir (PrOD) regime in treatment-naive patients with hepatitis C regardless of kidney disease. Most of our renal transplant (RT) recipients were treated with PrOD. The aim of the p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Turk J Gastroenterol
Main Authors: Danış, Nilay, Toz, Hüseyin, Ünal, Nalan, Yılmaz, Mümtaz, Turan, İlker, Günşar, Fulya, Karasu, Zeki, Ersöz, Galip, Özkahya, Mehmet, Akarca, Ulus Salih
Formato: Artigo
Idioma:Inglês
Publicado em: Turkish Society of Gastroenterology 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699569/
https://ncbi.nlm.nih.gov/pubmed/31418413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.18833
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados